Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patient...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Transl Med
Main Authors: Liu, An‐Dong, Zhou, Jie, Bi, Xiao‐Yang, Hou, Guo‐Qing, Li, Shawn Shun‐Cheng, Chen, Qing, Xu, Hui, Cao, Xuan
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2021
主題:
Research Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7908048/
https://ncbi.nlm.nih.gov/pubmed/33783993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.337
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍